Breastfeeding Support for High Blood Pressure Postpartum
(sheMATTERS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Hypertensive disorders of pregnancy (HDP) are increasingly recognized sex-specific risk factors for premature cardiovascular disease (CVD) in women. HDP, including preeclampsia and gestational hypertension, confer a 2- to 3-fold increase in the risk of chronic hypertension and ischemic heart disease 10-15 years after delivery. Observational data suggest that breastfeeding can lower maternal blood pressure (BP), risk of metabolic syndrome, and other markers of cardiovascular risk in the short term and long term, possibly by helping to re-set the metabolic changes of pregnancy. The investigators recently demonstrated an 11% reduction in the risk of metabolic syndrome among postpartum women with a variety of complications in pregnancy, including HDP, who breastfed for \> 6 months, compared to those who did not breastfeed and those who breastfed for shorter durations. An analysis of 622 postpartum women at Kingston General Hospital showed that breastfeeding women had nearly a 6-mmHg lower systolic BP than women who did not breastfeed with an apparent dose-response effect of breastfeeding duration. Women with pregnancy complications including HDP are vulnerable to early weaning. Interactive, multi-modal approaches targeting a mother's breastfeeding self-efficacy (i.e., confidence about breastfeeding) have been effective in healthy postpartum women. However, these have not yet been tested specifically in HDP women, who stand to derive substantial benefit from breastfeeding. This is an important area to study since nurse-led breastfeeding supportive interventions can be widely applied to the postpartum care of women with HDP and can be integrated into comprehensive CVD risk reduction programs for these women. The primary outcome is postpartum BP, since hypertension is a key mediating factor in women's heart health. The investigators conducted a feasibility study of a breastfeeding self-efficacy intervention to enhance breastfeeding outcomes among women with HDP achieving pre-defined targets of a recruitment rate of \>50% , attrition rates of \< 30%, and \> 70% participant satisfaction with the intervention, measured at the 6-month time point. Additionally, data showed trends in both systolic and diastolic BP favoring the intervention group. The current study is a multi-site open-label randomized trial to assess for a difference in blood pressure and breastfeeding between groups, and to serve as a cohort of HDP women for longitudinal follow-up.
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop taking your current medications. However, if you are taking medication that makes breastfeeding unsafe, you may not be eligible to participate.
Is breastfeeding self-efficacy intervention safe for humans?
How does the breastfeeding support treatment for high blood pressure postpartum differ from other treatments?
This treatment is unique because it focuses on increasing breastfeeding self-efficacy (confidence in one's ability to breastfeed), which can indirectly help manage high blood pressure postpartum by promoting sustained breastfeeding. Unlike traditional medical treatments for high blood pressure, this approach emphasizes psychological support and education to improve breastfeeding success.678910
What data supports the effectiveness of the treatment Breastfeeding self-efficacy (BSE) for high blood pressure postpartum?
Who Is on the Research Team?
Natalie Dayan, MD, MSc
Principal Investigator
McGill University Health Center- Research Institute of the McGill University Health Center
Sonia Semenic, N, PhD
Principal Investigator
Associate Professor and PhD Program Ingram School of Nursing, McGill University
Graeme Smith, MD, PhD
Principal Investigator
Prof. Head Dept Obstetrics - Gynaecology, Dept. Biomedical and Molecular Sciences Queen's University
Atanas Nedelchev, MD
Principal Investigator
Assistant Professor, Department of Obstetrics and Gynecology
Haim Abenhaim, MD, MPH
Principal Investigator
Jewish General Hospital
Are You a Good Fit for This Trial?
This trial is for women over 18 who've given birth to a single baby at or after 34 weeks, plan and have started breastfeeding, speak English or French, have health coverage (RAMQ/OHIP), can use a cellphone with internet for BP monitoring and live near Montreal/Kingston. It's not for those with conditions that prevent breastfeeding, severe mental illness, substance abuse issues, COVID-19 during hospitalization or specific neonatal complications.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a nurse-led breastfeeding self-efficacy intervention to improve breastfeeding practices and lower blood pressure
Follow-up
Participants are monitored for blood pressure and breastfeeding outcomes, with passive follow-up for cardiovascular risk factors
What Are the Treatments Tested in This Trial?
Interventions
- Breastfeeding self-efficacy (BSE)
Find a Clinic Near You
Who Is Running the Clinical Trial?
McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead Sponsor
McGill University
Collaborator
Heart and Stroke Foundation of Canada
Collaborator